

# CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

---

## SIXTH SUPPLEMENTAL AGREEMENT TO THE LOAN AGREEMENT RELATING TO THE LOAN OF HK\$20,000,000 GRANTED TO THE COMPANY'S SUBSIDIARY

---

*Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings as defined in the announcements released on 20 June 2016, 13 December 2016, 29 March 2017, 27 June 2017, 27 December 2017 and 27 June 2018 in respect of the Loan Agreement (the "Previous Announcements").*

The board of directors (the "**Board**" of the "**Directors**") of China Medical (International) Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Previous Announcements and wishes to announce that the Company's wholly own subsidiary, CMIC Hemodialysis (Hong Kong) Limited (the "**Subsidiary**") has on 27 December 2018 entered into a sixth supplemental agreement (the "**Sixth Supplemental Agreement**") with Concorde Global Limited (the "**Lender**") to amend and supplement the Loan Agreement, the Supplemental Agreement, the Second Supplemental Agreement, the Third Supplemental Agreement, the Fourth Supplemental Agreement and the Fifth Supplemental Agreement.

Pursuant to the Sixth Supplemental Agreement, it was agreed, *inter alia*, that the Maturity Date (as defined below) be extended to 28 January 2019, and that the Subsidiary shall pay to the Lender interest on the Outstanding Amount (as defined below) at a rate of 16.0% per annum (instead of 14.0% per annum) from the date of the Sixth Supplemental Agreement until the Outstanding Amount is repaid in full.

As at the date of the Sixth Supplemental Agreement, there is an outstanding amount of HK\$20,000,000 (equivalent to S\$3,506,000<sup>(1)</sup>) due from the Subsidiary to the Lender (the "**Outstanding Amount**") which will be due on 27 December 2018 ("**Maturity Date**"). The Subsidiary is required to pay to the Lender an additional payment of HK\$200,000, being the extension fee incurred as a result of the entry into the Sixth Supplemental Agreement. Accordingly, aggregate liability of the Subsidiary will increase to S\$3.6 million.

As announced on 26 August 2018 and 7 December 2018, the Company is currently seeking shareholder's approval for its proposed corporate exercises to raise funds for the purpose of, *inter alia*, repaying its abovementioned outstanding loan obligations.

Except as to the extent varied or amended by the provisions of the Sixth Supplemental Agreement, the terms and conditions of the Loan Agreement, the Supplemental Agreement, the Second Supplemental Agreement, the Third Supplemental Agreement, the Fourth Supplemental Agreement and the Fifth Supplemental Agreement shall remain in full force and effect.

**Note:**

- (1) The exchange rate of HKD100.00: S\$17.53 as at 27 December 2018 was used for the conversion. The exchange rate has been extracted from information published by the Monetary Authority of Singapore.

**BY ORDER OF THE BOARD**  
**27 December 2018**

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*